Lenvatinib/Lenvatinib (Lenvima) common side effects and treatment methods

Lenvatinib/Lenvatinib (Lenvatinib) is a multi-target inhibitor. Its side effect spectrum in the treatment of renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and endometrial cancer is closely related to the inhibition of angiogenesis and the intervention of multiple signaling pathways. Clinical experience shows that hypertension is one of the more common adverse reactions, which is related to the drug's inhibition of the vascular endothelial growth factor pathway. Therefore, regular monitoring of blood pressure is considered a routine management measure during the initial period of medication and during follow-up. By rational use of antihypertensive drugs, most patients can maintain stable blood pressure without affecting anti-tumor treatment.

Digestive system reactions are also common, including loss of appetite, diarrhea, or weight changes. Most of these symptoms are controllable reactions, which can often be alleviated through dietary adjustments and symptomatic supportive treatment. Some patients may also experience fatigue, skin discomfort on hands and feet, or oral mucosal changes. These reactions are not uncommon in multi-target TKI treatment and are usually related to drug dosage and individual tolerance.

In terms of laboratory indicators, changes in liver function and thyroid function also require attention. Medical websites generally recommend regular examinations during treatment to detect abnormalities early and adjust treatment strategies. For patients who experience obvious adverse reactions, short-term reduction or suspension of medication can often improve symptoms, and then treatment can be resumed after a doctor's evaluation.

Overall, the adverse reactions of lenvatinib are “predictable and interventionable”. Through standardized follow-up, reasonable dose adjustment, and adequate communication between doctors and patients, most patients can continue to benefit under the premise of safety and controllability. This is also one of the important reasons why lenvatinib has been used for a long time in the treatment of various tumors.

Reference materials:https://www.lenvima.com/